AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

AbbVie (ABBV) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a ...

Good morning, and welcome to AbbVie second quarter 2024 earnings conference call. [Operator instructions] I would now like to introduce Ms. Liz Shea, senior vice president, investor relations. Liz ...

AbbVie ABBV will report second-quarter earnings on Jul 25, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $14.05 billion and $2.56 per share, respectively.

AbbVie's Q3 earnings will be announced on October 27th. Read why I consider ABBV stock as a de-risked investment opportunity with a generous dividend yield.

AbbVie ABBV will report second-quarter 2022 results on Jul 29, before market open. In the last reported quarter, the company delivered an earnings surprise of 0.32%. AbbVie’s stock has risen 11% ...

AbbVie Stock Trend Bullish Ahead Of Q2 Earnings AbbVie's stock shows a strongly bullish trend, with the share price of $173.15 surpassing its 5, 20, and 50-day exponential moving averages.

AbbVie Inc. reported Q2 adjusted EPS of $2.65, beating the $2.57 consensus, with net revenues at $14.46 billion. Immunology sales rose to $6.97 billion, while Humira declined 29.8%. Oncology and ...